ArticleChina CDC weekly2025
Efficacy Evaluation of Virus Clearance of SYN023 in A Murine Rabies Model - China, 2025.
Article in China CDC weekly, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Let's Act Now to Make Rabies History.China CDC weekly · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
What is already known about this topic?: Rabies is a fatal, but preventable, viral disease. Post-exposure prophylaxis (PEP), which includes the administration of passive immune preparations, is critical after exposure to the rabies virus, particularly in high-risk cases. The delayed or missed application of passive immunizing agents may increase the risk of infection. What is added by this report?: SYN023, a novel anti-rabies monoclonal antibody cocktail, can effectively reverse the course of rabies infection, even at a late stage of the disease. In a mouse model infected with the rabies virus strain SC16, multiple high-dose injections of SYN023 administered 5 days post-inoculation rescued 69% of the animals. What are the implications for public health practice?: These findings suggest that SYN023 could serve as a promising therapeutic agent for rabies PEP, particularly in cases in which treatment initiation is delayed. This study provides a scientific basis for future clinical trials aimed at improving rabies treatment protocols.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.